Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of PEX168 in Renal Insufficiency
NCT02467790Phase 1Unknown
- Sponsor
- Hansoh Pharmaceutical Group
- Start
- Feb 2015
- Primary completion
- Mar 2016
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, open-label trial of polyethylene glycol loxenatide in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Hansoh Pharmaceutical Group. Primary endpoint: Pharmacokinetic index. Status: unknown.
02
Drugs
polyethylene glycol loxenatide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02467790.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02467790.